Chinese expert consensus: Radioactive iodine-125 seed interstitial brachytherapy for retroperitoneal lymph node metastases (2024 edition).

OBJECTIVE

In order to standardize the operational techniques for 125I seed interstitial brachytherapy for retroperitoneal lymph node metastases, we organized multidisciplinary experts to develop the ".

CHINESE EXPERT CONSENSUS: radioactive iodine 125 seed interstitial brachytherapy for retroperitoneal lymph node metastases (2024 edition)."

METHOD: In the development of this consensus, we convened a multidisciplinary panel of leading Chinese medical experts specializing in seeds implantation from the fields of radiation oncology, surgery, interventional radiology, Department of Medical Oncology, ultrasonography, and nuclear medicine.

THE PROCESS PROCEEDED AS FOLLOWS: first, a literature search was conducted using keywords such as "iodine 125 seed implantation," "interstitial brachytherapy," "retroperitoneal lymph node metastases," "computed tomography-guided," and "125I seeds." Based on the reviewed literature and extensive clinical experience, the writing committee drafted the initial document. This draft was then distributed to all panel members for broad feedback and suggestions. Finally, a centralized discussion was held to integrate the collective expertise and finalize the consensus statements.

RESULT: The main contents of this consensus include indications, contraindications, implantation methods, puncture paths, dosage, surgical procedures, and other key points.

CONCLUSION

This consensus document demonstrates a high degree of scientific rigor and practical applicability. It is designed to provide clinical guidance for the implementation of 125I seed brachytherapy for retroperitoneal lymph node metastases. By establishing clear, evidence-based recommendations, it aims to serve as a reliable reference for clinicians, nurses, and medical physicists involved in the procedure. Ultimately, this consensus seeks to enhance the standardization and procedural homogeneity of 125I seed brachytherapy for retroperitoneal lymph node metastases across different clinical settings.